secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYADIC INTERNATIONAL INC (DYAI)
CIK:        0001213809
Form:       8-K
Filed at:   2026-06-15T20:30:17+00:00
Accession:  0001493152-26-028700
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyadic highlights accelerated C1 platform interest amid Ebola preparedness and commercial adoption
--------------------------------------------------------------------------------

- C1 platform can produce purified antigen or monoclonal antibody in ~15 days, says company.
- Collaborations: Scripps Research (Ebola, hantaviruses); CEPI Ebola funding proposals; Fondazione Biotecnopolo di Siena (Ebola, hantavirus antibodies).
- Commercial milestones: recombinant human albumin via Proliant Health; recombinant DNase I via Fermbox Bio; bovine chymosin via Inzymes.
- Estimated addressable market >$25B across life sciences, food/nutrition, bioindustrial applications.
- DYAI-100 clinical study showed C1-produced antigens were generally safe and well tolerated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213809/000149315226028700/0001493152-26-028700-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213809/000149315226028700/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-028700

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer